Nanobiotix (NASDAQ:NBTX) Stock Price Down 6.8% – Should You Sell?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) was down 6.8% on Thursday. The company traded as low as $23.23 and last traded at $22.9560. Approximately 9,660 shares changed hands during trading, a decline of 90% from the average session volume of 92,531 shares. The stock had previously closed at $24.62.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on NBTX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research note on Friday, July 17th. Guggenheim initiated coverage on Nanobiotix in a report on Tuesday, September 15th. They issued a “buy” rating and a $64.00 price target for the company. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $46.67.

Nanobiotix Price Performance

The business’s fifty day simple moving average is $36.36 and its two-hundred day simple moving average is $36.91.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. Headquartered in France, the company uses its proprietary NanoXray technology to design nanoparticles intended to enhance the effects of radiotherapy within solid tumors.

Nanobiotix’s lead product candidate, NBTXR3, is an investigational radioenhancer composed of hafnium oxide nanoparticles. Administered directly into a tumor before radiotherapy, NBTXR3 is designed to increase energy deposition in cancer cells when exposed to X-rays, with the goal of improving tumor control while using established radiation-treatment techniques.

The company is evaluating NBTXR3 in clinical studies across several cancer indications, including locally advanced soft-tissue sarcoma and head and neck cancers, as well as other solid tumors.